nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Ethinyl Estradiol—osteoporosis	0.0766	0.133	CbGbCtD
Tolvaptan—CYP3A4—Estropipate—osteoporosis	0.0712	0.124	CbGbCtD
Tolvaptan—CYP3A4—Calcitriol—osteoporosis	0.0712	0.124	CbGbCtD
Tolvaptan—CYP3A4—Ergocalciferol—osteoporosis	0.057	0.099	CbGbCtD
Tolvaptan—ABCB1—Conjugated Estrogens—osteoporosis	0.0562	0.0978	CbGbCtD
Tolvaptan—ABCB1—Estradiol—osteoporosis	0.0494	0.0859	CbGbCtD
Tolvaptan—CYP3A4—Raloxifene—osteoporosis	0.0475	0.0827	CbGbCtD
Tolvaptan—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0459	0.0798	CbGbCtD
Tolvaptan—CYP3A4—Cholecalciferol—osteoporosis	0.0367	0.0638	CbGbCtD
Tolvaptan—CYP3A4—Conjugated Estrogens—osteoporosis	0.0337	0.0586	CbGbCtD
Tolvaptan—CYP3A4—Estradiol—osteoporosis	0.0296	0.0514	CbGbCtD
Tolvaptan—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00454	0.067	CbGpPWpGaD
Tolvaptan—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.0028	0.0413	CbGpPWpGaD
Tolvaptan—AVPR2—G alpha (s) signalling events—CALCR—osteoporosis	0.00266	0.0393	CbGpPWpGaD
Tolvaptan—AVPR2—G alpha (s) signalling events—PTH1R—osteoporosis	0.00266	0.0393	CbGpPWpGaD
Tolvaptan—AVPR2—Vasopressin regulates renal water homeostasis via Aquaporins—ADCY5—osteoporosis	0.00169	0.025	CbGpPWpGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—MGLL—osteoporosis	0.00154	0.0226	CbGpPWpGaD
Tolvaptan—AVPR2—Aquaporin-mediated transport—ADCY5—osteoporosis	0.00148	0.0218	CbGpPWpGaD
Tolvaptan—AVPR2—G alpha (s) signalling events—PTH—osteoporosis	0.0014	0.0207	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.00137	0.0203	CbGpPWpGaD
Tolvaptan—AVPR2—G alpha (s) signalling events—PTHLH—osteoporosis	0.00116	0.0171	CbGpPWpGaD
Tolvaptan—AVPR2—G alpha (s) signalling events—CALCA—osteoporosis	0.00102	0.0151	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—PTH1R—osteoporosis	0.000975	0.0144	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CALCR—osteoporosis	0.000975	0.0144	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—PTH1R—osteoporosis	0.000968	0.0143	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CALCR—osteoporosis	0.000968	0.0143	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—PKM—osteoporosis	0.00093	0.0137	CbGpPWpGaD
Tolvaptan—Malaise—Alendronate—osteoporosis	0.000855	0.00239	CcSEcCtD
Tolvaptan—Syncope—Raloxifene—osteoporosis	0.000836	0.00234	CcSEcCtD
Tolvaptan—Malaise—Ibandronate—osteoporosis	0.000833	0.00233	CcSEcCtD
Tolvaptan—Renal failure—Zoledronate—osteoporosis	0.000831	0.00233	CcSEcCtD
Tolvaptan—Hyperglycaemia—Conjugated Estrogens—osteoporosis	0.000824	0.00231	CcSEcCtD
Tolvaptan—Nausea—Calcium Acetate—osteoporosis	0.000822	0.0023	CcSEcCtD
Tolvaptan—Urinary tract disorder—Pamidronate—osteoporosis	0.000821	0.0023	CcSEcCtD
Tolvaptan—Loss of consciousness—Raloxifene—osteoporosis	0.00082	0.0023	CcSEcCtD
Tolvaptan—Connective tissue disorder—Pamidronate—osteoporosis	0.000816	0.00229	CcSEcCtD
Tolvaptan—Urethral disorder—Pamidronate—osteoporosis	0.000814	0.00228	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.000814	0.00228	CcSEcCtD
Tolvaptan—Angiopathy—Ethinyl Estradiol—osteoporosis	0.000813	0.00228	CcSEcCtD
Tolvaptan—Cardiac disorder—Risedronate—osteoporosis	0.000811	0.00227	CcSEcCtD
Tolvaptan—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.00081	0.00227	CcSEcCtD
Tolvaptan—Renal failure—Conjugated Estrogens—osteoporosis	0.0008	0.00224	CcSEcCtD
Tolvaptan—Discomfort—Alendronate—osteoporosis	0.000798	0.00223	CcSEcCtD
Tolvaptan—Angiopathy—Risedronate—osteoporosis	0.000793	0.00222	CcSEcCtD
Tolvaptan—Immune system disorder—Risedronate—osteoporosis	0.000789	0.00221	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000788	0.00221	CcSEcCtD
Tolvaptan—Mediastinal disorder—Risedronate—osteoporosis	0.000788	0.00221	CcSEcCtD
Tolvaptan—Anaphylactic shock—Estropipate—osteoporosis	0.000786	0.0022	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.000781	0.00219	CcSEcCtD
Tolvaptan—Malnutrition—Ethinyl Estradiol—osteoporosis	0.00078	0.00219	CcSEcCtD
Tolvaptan—Constipation—Etidronic acid—osteoporosis	0.000777	0.00217	CcSEcCtD
Tolvaptan—Discomfort—Ibandronate—osteoporosis	0.000777	0.00217	CcSEcCtD
Tolvaptan—Cardiac disorder—Pamidronate—osteoporosis	0.000771	0.00216	CcSEcCtD
Tolvaptan—Nervous system disorder—Estropipate—osteoporosis	0.000771	0.00216	CcSEcCtD
Tolvaptan—Dry mouth—Ibandronate—osteoporosis	0.000769	0.00215	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000765	0.0113	CbGpPWpGaD
Tolvaptan—Breast disorder—Estradiol—osteoporosis	0.000764	0.00214	CcSEcCtD
Tolvaptan—Skin disorder—Estropipate—osteoporosis	0.000763	0.00214	CcSEcCtD
Tolvaptan—Malnutrition—Risedronate—osteoporosis	0.000761	0.00213	CcSEcCtD
Tolvaptan—Discomfort—Calcitriol—osteoporosis	0.00076	0.00213	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000759	0.0112	CbGpPWpGaD
Tolvaptan—Angiopathy—Pamidronate—osteoporosis	0.000754	0.00211	CcSEcCtD
Tolvaptan—Anaphylactic shock—Ibandronate—osteoporosis	0.000753	0.00211	CcSEcCtD
Tolvaptan—Dry mouth—Calcitriol—osteoporosis	0.000752	0.00211	CcSEcCtD
Tolvaptan—Immune system disorder—Pamidronate—osteoporosis	0.00075	0.0021	CcSEcCtD
Tolvaptan—Urinary tract disorder—Zoledronate—osteoporosis	0.000749	0.0021	CcSEcCtD
Tolvaptan—Mediastinal disorder—Pamidronate—osteoporosis	0.000749	0.0021	CcSEcCtD
Tolvaptan—Shock—Raloxifene—osteoporosis	0.000749	0.0021	CcSEcCtD
Tolvaptan—Feeling abnormal—Etidronic acid—osteoporosis	0.000748	0.0021	CcSEcCtD
Tolvaptan—Nervous system disorder—Raloxifene—osteoporosis	0.000746	0.00209	CcSEcCtD
Tolvaptan—Connective tissue disorder—Zoledronate—osteoporosis	0.000746	0.00209	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Estradiol—osteoporosis	0.000746	0.00209	CcSEcCtD
Tolvaptan—Urethral disorder—Zoledronate—osteoporosis	0.000744	0.00208	CcSEcCtD
Tolvaptan—Shock—Ibandronate—osteoporosis	0.000741	0.00208	CcSEcCtD
Tolvaptan—Skin disorder—Raloxifene—osteoporosis	0.000739	0.00207	CcSEcCtD
Tolvaptan—Nervous system disorder—Ibandronate—osteoporosis	0.000739	0.00207	CcSEcCtD
Tolvaptan—Anaphylactic shock—Calcitriol—osteoporosis	0.000738	0.00207	CcSEcCtD
Tolvaptan—Skin disorder—Ibandronate—osteoporosis	0.000732	0.00205	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—ADCY5—osteoporosis	0.000726	0.0107	CbGpPWpGaD
Tolvaptan—Nausea—Ergocalciferol—osteoporosis	0.000726	0.00203	CcSEcCtD
Tolvaptan—ABCB1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000726	0.0107	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Ethinyl Estradiol—osteoporosis	0.000724	0.00203	CcSEcCtD
Tolvaptan—Malnutrition—Pamidronate—osteoporosis	0.000723	0.00203	CcSEcCtD
Tolvaptan—Skin disorder—Calcitriol—osteoporosis	0.000716	0.00201	CcSEcCtD
Tolvaptan—Dysgeusia—Pamidronate—osteoporosis	0.000708	0.00198	CcSEcCtD
Tolvaptan—Cardiac disorder—Zoledronate—osteoporosis	0.000704	0.00197	CcSEcCtD
Tolvaptan—Malaise—Ethinyl Estradiol—osteoporosis	0.000704	0.00197	CcSEcCtD
Tolvaptan—Anorexia—Calcitriol—osteoporosis	0.000703	0.00197	CcSEcCtD
Tolvaptan—Angiopathy—Zoledronate—osteoporosis	0.000689	0.00193	CcSEcCtD
Tolvaptan—Immune system disorder—Zoledronate—osteoporosis	0.000685	0.00192	CcSEcCtD
Tolvaptan—Mediastinal disorder—Zoledronate—osteoporosis	0.000684	0.00192	CcSEcCtD
Tolvaptan—Syncope—Risedronate—osteoporosis	0.000682	0.00191	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Estropipate—osteoporosis	0.000678	0.0019	CcSEcCtD
Tolvaptan—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000678	0.0019	CcSEcCtD
Tolvaptan—Pollakiuria—Estradiol—osteoporosis	0.000675	0.00189	CcSEcCtD
Tolvaptan—Constipation—Estropipate—osteoporosis	0.000672	0.00188	CcSEcCtD
Tolvaptan—Ill-defined disorder—Pamidronate—osteoporosis	0.000671	0.00188	CcSEcCtD
Tolvaptan—Hypersensitivity—Etidronic acid—osteoporosis	0.000669	0.00187	CcSEcCtD
Tolvaptan—Loss of consciousness—Risedronate—osteoporosis	0.000669	0.00187	CcSEcCtD
Tolvaptan—Angiopathy—Conjugated Estrogens—osteoporosis	0.000663	0.00186	CcSEcCtD
Tolvaptan—Constipation—Alendronate—osteoporosis	0.000662	0.00185	CcSEcCtD
Tolvaptan—Malnutrition—Zoledronate—osteoporosis	0.000661	0.00185	CcSEcCtD
Tolvaptan—Immune system disorder—Conjugated Estrogens—osteoporosis	0.00066	0.00185	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00066	0.00185	CcSEcCtD
Tolvaptan—Hyperglycaemia—Estradiol—osteoporosis	0.000659	0.00185	CcSEcCtD
Tolvaptan—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000659	0.00184	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000657	0.00184	CcSEcCtD
Tolvaptan—Discomfort—Ethinyl Estradiol—osteoporosis	0.000656	0.00184	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000655	0.00967	CbGpPWpGaD
Tolvaptan—Decreased appetite—Ibandronate—osteoporosis	0.000655	0.00183	CcSEcCtD
Tolvaptan—Malaise—Pamidronate—osteoporosis	0.000652	0.00183	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00065	0.00182	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00065	0.0096	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TUBA1B—osteoporosis	0.000649	0.00958	CbGpPWpGaD
Tolvaptan—Syncope—Pamidronate—osteoporosis	0.000649	0.00182	CcSEcCtD
Tolvaptan—Dysgeusia—Zoledronate—osteoporosis	0.000647	0.00181	CcSEcCtD
Tolvaptan—Constipation—Ibandronate—osteoporosis	0.000644	0.0018	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000643	0.0018	CcSEcCtD
Tolvaptan—Pruritus—Etidronic acid—osteoporosis	0.000643	0.0018	CcSEcCtD
Tolvaptan—Decreased appetite—Calcitriol—osteoporosis	0.000641	0.0018	CcSEcCtD
Tolvaptan—Feeling abnormal—Alendronate—osteoporosis	0.000638	0.00179	CcSEcCtD
Tolvaptan—Malnutrition—Conjugated Estrogens—osteoporosis	0.000636	0.00178	CcSEcCtD
Tolvaptan—Loss of consciousness—Pamidronate—osteoporosis	0.000636	0.00178	CcSEcCtD
Tolvaptan—Dry mouth—Risedronate—osteoporosis	0.000633	0.00177	CcSEcCtD
Tolvaptan—Constipation—Calcitriol—osteoporosis	0.000631	0.00177	CcSEcCtD
Tolvaptan—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000625	0.00175	CcSEcCtD
Tolvaptan—Dysgeusia—Conjugated Estrogens—osteoporosis	0.000623	0.00174	CcSEcCtD
Tolvaptan—Diarrhoea—Etidronic acid—osteoporosis	0.000621	0.00174	CcSEcCtD
Tolvaptan—Body temperature increased—Estropipate—osteoporosis	0.000621	0.00174	CcSEcCtD
Tolvaptan—Feeling abnormal—Ibandronate—osteoporosis	0.000621	0.00174	CcSEcCtD
Tolvaptan—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000619	0.00173	CcSEcCtD
Tolvaptan—Ill-defined disorder—Zoledronate—osteoporosis	0.000613	0.00172	CcSEcCtD
Tolvaptan—Body temperature increased—Alendronate—osteoporosis	0.000612	0.00171	CcSEcCtD
Tolvaptan—Shock—Risedronate—osteoporosis	0.000611	0.00171	CcSEcCtD
Tolvaptan—Nervous system disorder—Risedronate—osteoporosis	0.000609	0.00171	CcSEcCtD
Tolvaptan—Discomfort—Pamidronate—osteoporosis	0.000608	0.0017	CcSEcCtD
Tolvaptan—Skin disorder—Risedronate—osteoporosis	0.000603	0.00169	CcSEcCtD
Tolvaptan—Body temperature increased—Raloxifene—osteoporosis	0.000602	0.00168	CcSEcCtD
Tolvaptan—Malaise—Zoledronate—osteoporosis	0.000596	0.00167	CcSEcCtD
Tolvaptan—Body temperature increased—Ibandronate—osteoporosis	0.000596	0.00167	CcSEcCtD
Tolvaptan—Syncope—Zoledronate—osteoporosis	0.000592	0.00166	CcSEcCtD
Tolvaptan—Anaphylactic shock—Pamidronate—osteoporosis	0.00059	0.00165	CcSEcCtD
Tolvaptan—Body temperature increased—Calcitriol—osteoporosis	0.000583	0.00163	CcSEcCtD
Tolvaptan—Shock—Pamidronate—osteoporosis	0.000581	0.00163	CcSEcCtD
Tolvaptan—Loss of consciousness—Zoledronate—osteoporosis	0.000581	0.00163	CcSEcCtD
Tolvaptan—Hypersensitivity—Estropipate—osteoporosis	0.000579	0.00162	CcSEcCtD
Tolvaptan—Nervous system disorder—Pamidronate—osteoporosis	0.000579	0.00162	CcSEcCtD
Tolvaptan—Urinary tract disorder—Estradiol—osteoporosis	0.000578	0.00162	CcSEcCtD
Tolvaptan—Connective tissue disorder—Estradiol—osteoporosis	0.000575	0.00161	CcSEcCtD
Tolvaptan—Urethral disorder—Estradiol—osteoporosis	0.000573	0.00161	CcSEcCtD
Tolvaptan—Syncope—Conjugated Estrogens—osteoporosis	0.00057	0.0016	CcSEcCtD
Tolvaptan—Hypersensitivity—Alendronate—osteoporosis	0.00057	0.0016	CcSEcCtD
Tolvaptan—Headache—Etidronic acid—osteoporosis	0.000569	0.00159	CcSEcCtD
Tolvaptan—Asthenia—Estropipate—osteoporosis	0.000564	0.00158	CcSEcCtD
Tolvaptan—Anorexia—Pamidronate—osteoporosis	0.000563	0.00158	CcSEcCtD
Tolvaptan—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000559	0.00157	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000559	0.00156	CcSEcCtD
Tolvaptan—Pruritus—Estropipate—osteoporosis	0.000556	0.00156	CcSEcCtD
Tolvaptan—Discomfort—Zoledronate—osteoporosis	0.000556	0.00156	CcSEcCtD
Tolvaptan—Asthenia—Alendronate—osteoporosis	0.000555	0.00155	CcSEcCtD
Tolvaptan—Hypersensitivity—Ibandronate—osteoporosis	0.000555	0.00155	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CALCR—osteoporosis	0.000551	0.00813	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PTH1R—osteoporosis	0.000551	0.00813	CbGpPWpGaD
Tolvaptan—Dry mouth—Zoledronate—osteoporosis	0.00055	0.00154	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00055	0.00154	CcSEcCtD
Tolvaptan—Pruritus—Alendronate—osteoporosis	0.000548	0.00153	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—CALCR—osteoporosis	0.000547	0.00807	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PTH1R—osteoporosis	0.000547	0.00807	CbGpPWpGaD
Tolvaptan—Constipation—Ethinyl Estradiol—osteoporosis	0.000545	0.00152	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000544	0.00803	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Calcitriol—osteoporosis	0.000543	0.00152	CcSEcCtD
Tolvaptan—Cardiac disorder—Estradiol—osteoporosis	0.000543	0.00152	CcSEcCtD
Tolvaptan—Asthenia—Ibandronate—osteoporosis	0.000541	0.00151	CcSEcCtD
Tolvaptan—Nausea—Etidronic acid—osteoporosis	0.000539	0.00151	CcSEcCtD
Tolvaptan—Anaphylactic shock—Zoledronate—osteoporosis	0.000539	0.00151	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000538	0.00151	CcSEcCtD
Tolvaptan—Diarrhoea—Estropipate—osteoporosis	0.000538	0.00151	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Risedronate—osteoporosis	0.000536	0.0015	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—POMC—osteoporosis	0.000534	0.00788	CbGpPWpGaD
Tolvaptan—Pruritus—Ibandronate—osteoporosis	0.000533	0.00149	CcSEcCtD
Tolvaptan—Constipation—Risedronate—osteoporosis	0.000531	0.00149	CcSEcCtD
Tolvaptan—Angiopathy—Estradiol—osteoporosis	0.000531	0.00149	CcSEcCtD
Tolvaptan—Shock—Zoledronate—osteoporosis	0.00053	0.00149	CcSEcCtD
Tolvaptan—Diarrhoea—Alendronate—osteoporosis	0.00053	0.00148	CcSEcCtD
Tolvaptan—Asthenia—Calcitriol—osteoporosis	0.000529	0.00148	CcSEcCtD
Tolvaptan—Nervous system disorder—Zoledronate—osteoporosis	0.000529	0.00148	CcSEcCtD
Tolvaptan—Immune system disorder—Estradiol—osteoporosis	0.000528	0.00148	CcSEcCtD
Tolvaptan—Mediastinal disorder—Estradiol—osteoporosis	0.000527	0.00148	CcSEcCtD
Tolvaptan—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000525	0.00147	CcSEcCtD
Tolvaptan—Skin disorder—Zoledronate—osteoporosis	0.000524	0.00147	CcSEcCtD
Tolvaptan—Pruritus—Calcitriol—osteoporosis	0.000522	0.00146	CcSEcCtD
Tolvaptan—Diarrhoea—Raloxifene—osteoporosis	0.000521	0.00146	CcSEcCtD
Tolvaptan—Dizziness—Estropipate—osteoporosis	0.00052	0.00145	CcSEcCtD
Tolvaptan—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000519	0.00145	CcSEcCtD
Tolvaptan—Diarrhoea—Ibandronate—osteoporosis	0.000516	0.00144	CcSEcCtD
Tolvaptan—Anorexia—Zoledronate—osteoporosis	0.000514	0.00144	CcSEcCtD
Tolvaptan—Decreased appetite—Pamidronate—osteoporosis	0.000513	0.00144	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—PTH—osteoporosis	0.000512	0.00755	CbGpPWpGaD
Tolvaptan—Dizziness—Alendronate—osteoporosis	0.000512	0.00143	CcSEcCtD
Tolvaptan—Shock—Conjugated Estrogens—osteoporosis	0.000511	0.00143	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00051	0.00143	CcSEcCtD
Tolvaptan—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000509	0.00143	CcSEcCtD
Tolvaptan—Malnutrition—Estradiol—osteoporosis	0.000509	0.00143	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—PTH—osteoporosis	0.000508	0.0075	CbGpPWpGaD
Tolvaptan—Constipation—Pamidronate—osteoporosis	0.000505	0.00141	CcSEcCtD
Tolvaptan—Diarrhoea—Calcitriol—osteoporosis	0.000505	0.00141	CcSEcCtD
Tolvaptan—Skin disorder—Conjugated Estrogens—osteoporosis	0.000504	0.00141	CcSEcCtD
Tolvaptan—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000503	0.00141	CcSEcCtD
Tolvaptan—Dizziness—Raloxifene—osteoporosis	0.000503	0.00141	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CALCR—osteoporosis	0.0005	0.00738	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTH1R—osteoporosis	0.0005	0.00738	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CNR2—osteoporosis	0.000499	0.00736	CbGpPWpGaD
Tolvaptan—Dysgeusia—Estradiol—osteoporosis	0.000499	0.0014	CcSEcCtD
Tolvaptan—Dizziness—Ibandronate—osteoporosis	0.000498	0.0014	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—CALCR—osteoporosis	0.000497	0.00733	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTH1R—osteoporosis	0.000497	0.00733	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CNR2—osteoporosis	0.000495	0.00731	CbGpPWpGaD
Tolvaptan—Anorexia—Conjugated Estrogens—osteoporosis	0.000495	0.00139	CcSEcCtD
Tolvaptan—Headache—Estropipate—osteoporosis	0.000492	0.00138	CcSEcCtD
Tolvaptan—Body temperature increased—Risedronate—osteoporosis	0.000491	0.00137	CcSEcCtD
Tolvaptan—Feeling abnormal—Pamidronate—osteoporosis	0.000486	0.00136	CcSEcCtD
Tolvaptan—Headache—Alendronate—osteoporosis	0.000485	0.00136	CcSEcCtD
Tolvaptan—Headache—Raloxifene—osteoporosis	0.000477	0.00134	CcSEcCtD
Tolvaptan—Ill-defined disorder—Estradiol—osteoporosis	0.000472	0.00132	CcSEcCtD
Tolvaptan—Headache—Ibandronate—osteoporosis	0.000472	0.00132	CcSEcCtD
Tolvaptan—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000469	0.00131	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—WNT1—osteoporosis	0.000469	0.00692	CbGpPWpGaD
Tolvaptan—Decreased appetite—Zoledronate—osteoporosis	0.000469	0.00131	CcSEcCtD
Tolvaptan—Nausea—Estropipate—osteoporosis	0.000467	0.00131	CcSEcCtD
Tolvaptan—Body temperature increased—Pamidronate—osteoporosis	0.000467	0.00131	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—WNT1—osteoporosis	0.000466	0.00687	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000465	0.0013	CcSEcCtD
Tolvaptan—Headache—Calcitriol—osteoporosis	0.000462	0.00129	CcSEcCtD
Tolvaptan—Constipation—Zoledronate—osteoporosis	0.000461	0.00129	CcSEcCtD
Tolvaptan—Nausea—Alendronate—osteoporosis	0.00046	0.00129	CcSEcCtD
Tolvaptan—Malaise—Estradiol—osteoporosis	0.000459	0.00129	CcSEcCtD
Tolvaptan—Hypersensitivity—Risedronate—osteoporosis	0.000457	0.00128	CcSEcCtD
Tolvaptan—Asthenia—Ethinyl Estradiol—osteoporosis	0.000457	0.00128	CcSEcCtD
Tolvaptan—Syncope—Estradiol—osteoporosis	0.000457	0.00128	CcSEcCtD
Tolvaptan—Nausea—Raloxifene—osteoporosis	0.000452	0.00127	CcSEcCtD
Tolvaptan—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000451	0.00126	CcSEcCtD
Tolvaptan—Pruritus—Ethinyl Estradiol—osteoporosis	0.000451	0.00126	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000448	0.00126	CcSEcCtD
Tolvaptan—Nausea—Ibandronate—osteoporosis	0.000448	0.00125	CcSEcCtD
Tolvaptan—Loss of consciousness—Estradiol—osteoporosis	0.000447	0.00125	CcSEcCtD
Tolvaptan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000447	0.0066	CbGpPWpGaD
Tolvaptan—Asthenia—Risedronate—osteoporosis	0.000446	0.00125	CcSEcCtD
Tolvaptan—Feeling abnormal—Zoledronate—osteoporosis	0.000444	0.00124	CcSEcCtD
Tolvaptan—Constipation—Conjugated Estrogens—osteoporosis	0.000444	0.00124	CcSEcCtD
Tolvaptan—Pruritus—Risedronate—osteoporosis	0.000439	0.00123	CcSEcCtD
Tolvaptan—Nausea—Calcitriol—osteoporosis	0.000438	0.00123	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—MGLL—osteoporosis	0.000438	0.00646	CbGpPWpGaD
Tolvaptan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000436	0.00122	CcSEcCtD
Tolvaptan—Hypersensitivity—Pamidronate—osteoporosis	0.000435	0.00122	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—MGLL—osteoporosis	0.000434	0.00641	CbGpPWpGaD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00043	0.00121	CcSEcCtD
Tolvaptan—Discomfort—Estradiol—osteoporosis	0.000428	0.0012	CcSEcCtD
Tolvaptan—Body temperature increased—Zoledronate—osteoporosis	0.000426	0.00119	CcSEcCtD
Tolvaptan—Diarrhoea—Risedronate—osteoporosis	0.000425	0.00119	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—PTHLH—osteoporosis	0.000424	0.00626	CbGpPWpGaD
Tolvaptan—Dry mouth—Estradiol—osteoporosis	0.000424	0.00119	CcSEcCtD
Tolvaptan—Asthenia—Pamidronate—osteoporosis	0.000424	0.00119	CcSEcCtD
Tolvaptan—Dizziness—Ethinyl Estradiol—osteoporosis	0.000421	0.00118	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—PTHLH—osteoporosis	0.000421	0.00621	CbGpPWpGaD
Tolvaptan—Pruritus—Pamidronate—osteoporosis	0.000418	0.00117	CcSEcCtD
Tolvaptan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000417	0.00615	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Estradiol—osteoporosis	0.000416	0.00116	CcSEcCtD
Tolvaptan—Dizziness—Risedronate—osteoporosis	0.000411	0.00115	CcSEcCtD
Tolvaptan—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00041	0.00115	CcSEcCtD
Tolvaptan—Shock—Estradiol—osteoporosis	0.000409	0.00114	CcSEcCtD
Tolvaptan—Nervous system disorder—Estradiol—osteoporosis	0.000407	0.00114	CcSEcCtD
Tolvaptan—Diarrhoea—Pamidronate—osteoporosis	0.000404	0.00113	CcSEcCtD
Tolvaptan—Skin disorder—Estradiol—osteoporosis	0.000404	0.00113	CcSEcCtD
Tolvaptan—Headache—Ethinyl Estradiol—osteoporosis	0.000399	0.00112	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—MGLL—osteoporosis	0.000397	0.00586	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Zoledronate—osteoporosis	0.000397	0.00111	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—MGLL—osteoporosis	0.000394	0.00582	CbGpPWpGaD
Tolvaptan—Dizziness—Pamidronate—osteoporosis	0.00039	0.00109	CcSEcCtD
Tolvaptan—Headache—Risedronate—osteoporosis	0.000389	0.00109	CcSEcCtD
Tolvaptan—Asthenia—Zoledronate—osteoporosis	0.000387	0.00108	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—POMC—osteoporosis	0.000383	0.00564	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000383	0.00107	CcSEcCtD
Tolvaptan—Pruritus—Zoledronate—osteoporosis	0.000381	0.00107	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—POMC—osteoporosis	0.00038	0.0056	CbGpPWpGaD
Tolvaptan—Nausea—Ethinyl Estradiol—osteoporosis	0.000378	0.00106	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CALCA—osteoporosis	0.000373	0.00551	CbGpPWpGaD
Tolvaptan—Asthenia—Conjugated Estrogens—osteoporosis	0.000372	0.00104	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—CALCA—osteoporosis	0.000371	0.00547	CbGpPWpGaD
Tolvaptan—Headache—Pamidronate—osteoporosis	0.00037	0.00104	CcSEcCtD
Tolvaptan—Diarrhoea—Zoledronate—osteoporosis	0.000369	0.00103	CcSEcCtD
Tolvaptan—Nausea—Risedronate—osteoporosis	0.000369	0.00103	CcSEcCtD
Tolvaptan—Pruritus—Conjugated Estrogens—osteoporosis	0.000367	0.00103	CcSEcCtD
Tolvaptan—Decreased appetite—Estradiol—osteoporosis	0.000361	0.00101	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Estradiol—osteoporosis	0.000359	0.001	CcSEcCtD
Tolvaptan—Dizziness—Zoledronate—osteoporosis	0.000357	0.000998	CcSEcCtD
Tolvaptan—Constipation—Estradiol—osteoporosis	0.000355	0.000995	CcSEcCtD
Tolvaptan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000355	0.000995	CcSEcCtD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000355	0.00524	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000351	0.00518	CbGpPWpGaD
Tolvaptan—Nausea—Pamidronate—osteoporosis	0.000351	0.000982	CcSEcCtD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00035	0.00517	CbGpPWpGaD
Tolvaptan—Dizziness—Conjugated Estrogens—osteoporosis	0.000343	0.000961	CcSEcCtD
Tolvaptan—Feeling abnormal—Estradiol—osteoporosis	0.000342	0.000959	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000338	0.00499	CbGpPWpGaD
Tolvaptan—Headache—Zoledronate—osteoporosis	0.000338	0.000946	CcSEcCtD
Tolvaptan—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000335	0.00494	CbGpPWpGaD
Tolvaptan—Body temperature increased—Estradiol—osteoporosis	0.000328	0.00092	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—SOST—osteoporosis	0.000327	0.00482	CbGpPWpGaD
Tolvaptan—Headache—Conjugated Estrogens—osteoporosis	0.000325	0.000911	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—SOST—osteoporosis	0.000324	0.00479	CbGpPWpGaD
Tolvaptan—Nausea—Zoledronate—osteoporosis	0.00032	0.000897	CcSEcCtD
Tolvaptan—Nausea—Conjugated Estrogens—osteoporosis	0.000308	0.000864	CcSEcCtD
Tolvaptan—Hypersensitivity—Estradiol—osteoporosis	0.000306	0.000857	CcSEcCtD
Tolvaptan—Asthenia—Estradiol—osteoporosis	0.000298	0.000835	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—CALCR—osteoporosis	0.000295	0.00436	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTH1R—osteoporosis	0.000295	0.00436	CbGpPWpGaD
Tolvaptan—Pruritus—Estradiol—osteoporosis	0.000294	0.000823	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—CALCR—osteoporosis	0.000293	0.00433	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTH1R—osteoporosis	0.000293	0.00433	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PTH—osteoporosis	0.000289	0.00427	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000288	0.00425	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PTH—osteoporosis	0.000287	0.00424	CbGpPWpGaD
Tolvaptan—Diarrhoea—Estradiol—osteoporosis	0.000284	0.000796	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CNR2—osteoporosis	0.000282	0.00416	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CNR2—osteoporosis	0.00028	0.00413	CbGpPWpGaD
Tolvaptan—Dizziness—Estradiol—osteoporosis	0.000275	0.000769	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—PTH—osteoporosis	0.000263	0.00388	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTH—osteoporosis	0.000261	0.00385	CbGpPWpGaD
Tolvaptan—Headache—Estradiol—osteoporosis	0.00026	0.000729	CcSEcCtD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000257	0.00379	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000257	0.00379	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CNR2—osteoporosis	0.000256	0.00378	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000255	0.00376	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CNR2—osteoporosis	0.000254	0.00375	CbGpPWpGaD
Tolvaptan—Nausea—Estradiol—osteoporosis	0.000247	0.000691	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—WNT1—osteoporosis	0.000241	0.00355	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PTHLH—osteoporosis	0.00024	0.00354	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—WNT1—osteoporosis	0.000239	0.00353	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PTHLH—osteoporosis	0.000238	0.00351	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MGLL—osteoporosis	0.000235	0.00346	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MGLL—osteoporosis	0.000233	0.00344	CbGpPWpGaD
Tolvaptan—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000231	0.0034	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—LRP5—osteoporosis	0.000229	0.00338	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—LRP5—osteoporosis	0.000227	0.00336	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—LRP6—osteoporosis	0.000219	0.00323	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTHLH—osteoporosis	0.000218	0.00321	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—LRP6—osteoporosis	0.000218	0.00321	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTHLH—osteoporosis	0.000216	0.00319	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CALCA—osteoporosis	0.000211	0.00311	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CALCA—osteoporosis	0.00021	0.00309	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000204	0.00301	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000196	0.0029	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—POMC—osteoporosis	0.000195	0.00288	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—POMC—osteoporosis	0.000194	0.00286	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CALCA—osteoporosis	0.000192	0.00283	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CALCA—osteoporosis	0.00019	0.00281	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000186	0.00275	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000185	0.00274	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TLN1—osteoporosis	0.000185	0.00273	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000184	0.00272	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TLN1—osteoporosis	0.000184	0.00271	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—P4HB—osteoporosis	0.00016	0.00235	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—P4HB—osteoporosis	0.000158	0.00234	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTH—osteoporosis	0.000155	0.00229	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTH—osteoporosis	0.000154	0.00227	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000153	0.00226	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RAP1A—osteoporosis	0.000153	0.00225	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RAP1A—osteoporosis	0.000151	0.00223	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CNR2—osteoporosis	0.000151	0.00223	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000151	0.00223	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000151	0.00222	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000151	0.00222	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CNR2—osteoporosis	0.00015	0.00222	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—ADCY5—osteoporosis	0.00015	0.00221	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—ADCY5—osteoporosis	0.000149	0.0022	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NFATC1—osteoporosis	0.000149	0.0022	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NFATC1—osteoporosis	0.000148	0.00218	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—DKK1—osteoporosis	0.000148	0.00218	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—DKK1—osteoporosis	0.000147	0.00216	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—WNT1—osteoporosis	0.000142	0.0021	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—WNT1—osteoporosis	0.000141	0.00208	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FGA—osteoporosis	0.000138	0.00204	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FGA—osteoporosis	0.000137	0.00203	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ADCY5—osteoporosis	0.000136	0.00201	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ADCY5—osteoporosis	0.000135	0.002	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000132	0.00195	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTHLH—osteoporosis	0.000129	0.0019	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—BMP2—osteoporosis	0.000129	0.0019	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTHLH—osteoporosis	0.000128	0.00188	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—BMP2—osteoporosis	0.000128	0.00188	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FGB—osteoporosis	0.000126	0.00186	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FGB—osteoporosis	0.000125	0.00184	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	0.000124	0.00182	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PSMA2—osteoporosis	0.000121	0.00179	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PSMA5—osteoporosis	0.000121	0.00179	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PSMA2—osteoporosis	0.000121	0.00178	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PSMA5—osteoporosis	0.000121	0.00178	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CALCA—osteoporosis	0.000113	0.00167	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CALCA—osteoporosis	0.000112	0.00166	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000112	0.00165	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—POMC—osteoporosis	0.00011	0.00163	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—POMC—osteoporosis	0.00011	0.00162	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL1B—osteoporosis	0.000108	0.0016	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000104	0.00153	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KL—osteoporosis	0.000103	0.00152	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KL—osteoporosis	0.000102	0.00151	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—POMC—osteoporosis	0.0001	0.00148	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—POMC—osteoporosis	9.96e-05	0.00147	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL6R—osteoporosis	9.78e-05	0.00144	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL6R—osteoporosis	9.71e-05	0.00143	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	9.09e-05	0.00134	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TGFB1—osteoporosis	8.42e-05	0.00124	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ADCY5—osteoporosis	8.05e-05	0.00119	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	8.03e-05	0.00118	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	8.01e-05	0.00118	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ADCY5—osteoporosis	8e-05	0.00118	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	7.92e-05	0.00117	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TNF—osteoporosis	7.86e-05	0.00116	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SPP1—osteoporosis	7.79e-05	0.00115	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SPP1—osteoporosis	7.74e-05	0.00114	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—FDPS—osteoporosis	7.39e-05	0.00109	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PKM—osteoporosis	7.39e-05	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IRS2—osteoporosis	7.05e-05	0.00104	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PGLS—osteoporosis	7e-05	0.00103	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GPD2—osteoporosis	7e-05	0.00103	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IRS2—osteoporosis	7e-05	0.00103	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	6.93e-05	0.00102	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—LEP—osteoporosis	6.9e-05	0.00102	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—LEP—osteoporosis	6.85e-05	0.00101	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ESR1—osteoporosis	6.58e-05	0.000971	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ESR1—osteoporosis	6.54e-05	0.000964	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PNP—osteoporosis	6.41e-05	0.000945	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ATIC—osteoporosis	6.41e-05	0.000945	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IRS1—osteoporosis	6.15e-05	0.000908	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IRS1—osteoporosis	6.11e-05	0.000901	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—POMC—osteoporosis	5.92e-05	0.000874	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—POMC—osteoporosis	5.88e-05	0.000868	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL6R—osteoporosis	5.78e-05	0.000853	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL6R—osteoporosis	5.74e-05	0.000846	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IGF1—osteoporosis	5.7e-05	0.000841	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IGF1—osteoporosis	5.66e-05	0.000835	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—OXCT1—osteoporosis	5.45e-05	0.000804	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CA2—osteoporosis	5.45e-05	0.000804	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—MGLL—osteoporosis	5.31e-05	0.000783	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—POMC—osteoporosis	4.83e-05	0.000712	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PKM—osteoporosis	4.55e-05	0.000672	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—FDPS—osteoporosis	4.55e-05	0.000672	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—IDH2—osteoporosis	4.51e-05	0.000666	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL6—osteoporosis	4.36e-05	0.000643	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL6—osteoporosis	4.33e-05	0.000638	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GPD2—osteoporosis	4.32e-05	0.000637	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PGLS—osteoporosis	4.32e-05	0.000637	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP27A1—osteoporosis	4.24e-05	0.000626	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	4.16e-05	0.000614	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	4.15e-05	0.000613	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ACP5—osteoporosis	4.13e-05	0.000609	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ATIC—osteoporosis	3.95e-05	0.000582	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PNP—osteoporosis	3.95e-05	0.000582	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.89e-05	0.000574	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.88e-05	0.000572	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TPI1—osteoporosis	3.84e-05	0.000566	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—P4HB—osteoporosis	3.61e-05	0.000532	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GAPDH—osteoporosis	3.54e-05	0.000523	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—RAP1A—osteoporosis	3.45e-05	0.000509	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MYC—osteoporosis	3.42e-05	0.000505	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TGFB1—osteoporosis	3.42e-05	0.000504	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MYC—osteoporosis	3.4e-05	0.000502	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TGFB1—osteoporosis	3.39e-05	0.0005	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—OXCT1—osteoporosis	3.36e-05	0.000495	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CA2—osteoporosis	3.36e-05	0.000495	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—MGLL—osteoporosis	3.27e-05	0.000483	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ENO1—osteoporosis	2.79e-05	0.000411	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—IDH2—osteoporosis	2.78e-05	0.00041	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PSMA2—osteoporosis	2.75e-05	0.000405	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PSMA5—osteoporosis	2.75e-05	0.000405	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.61e-05	0.000386	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL6—osteoporosis	2.57e-05	0.00038	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL6—osteoporosis	2.56e-05	0.000377	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ACP5—osteoporosis	2.54e-05	0.000375	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TPI1—osteoporosis	2.36e-05	0.000349	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP19A1—osteoporosis	2.23e-05	0.000329	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—P4HB—osteoporosis	2.22e-05	0.000328	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GAPDH—osteoporosis	2.18e-05	0.000322	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—RAP1A—osteoporosis	2.13e-05	0.000314	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ADCY5—osteoporosis	1.82e-05	0.000269	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GPX1—osteoporosis	1.82e-05	0.000268	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ENO1—osteoporosis	1.72e-05	0.000253	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PSMA2—osteoporosis	1.69e-05	0.00025	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PSMA5—osteoporosis	1.69e-05	0.00025	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—MTHFR—osteoporosis	1.68e-05	0.000247	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.37e-05	0.000203	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—POMC—osteoporosis	1.34e-05	0.000198	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ADCY5—osteoporosis	1.12e-05	0.000166	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GPX1—osteoporosis	1.12e-05	0.000165	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—MTHFR—osteoporosis	1.03e-05	0.000152	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—POMC—osteoporosis	8.25e-06	0.000122	CbGpPWpGaD
